AQ002P

AQ002P is a small molecule corticosteroid formulation developed by Aquilon Pharma (also known as Aquoralon Pharmaceuticals) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The drug is delivered via dry powder inhalation (DPI) and utilizes the company's proprietary excipient technology. This technology is designed to optimize the aerodynamic properties of the powder, enhancing the deposition of the corticosteroid in the lower respiratory tract. By improving lung delivery, AQ002P aims to provide superior anti-inflammatory efficacy with potentially lower doses and reduced systemic side effects compared to conventional inhaled corticosteroid formulations. As a corticosteroid, its primary mechanism of action involves the activation of the glucocorticoid receptor to modulate gene expression and suppress airway inflammation.

Other names

AQ002PAQ-002PAQ 002P